[Update on current care guidelines: atrial fibrillation]

Area of Science:

• Cardiology
• Pharmacology
• Clinical Guidelines

Background:

• Atrial fibrillation (AF) management requires continuous updates to incorporate new evidence and therapeutic options.
• Existing guidelines may not fully address symptom burden, thrombotic risk, bleeding risk, and novel treatment modalities.

Purpose of the Study:

• To outline the updated Finnish guidelines for managing patients with atrial fibrillation (AF).
• To highlight new recommendations for symptom assessment, risk stratification, and pharmacological and interventional treatments.

Main Methods:

• The Finnish guidelines were updated based on current scientific evidence and expert consensus.
• Key changes include the adoption of the EHRA score for symptom evaluation.
• Introduction of CHA DS VASc and HAS-BLED scores for risk stratification of thrombotic and bleeding events, respectively.

Main Results:

• The guidelines recommend using the EHRA score for evaluating AF-related symptoms.
• Comprehensive CHA DS VASc and HAS-BLED scoring systems are introduced for risk stratification.
• Recommendations for two new antiarrhythmic drugs, vernakalant (for cardioversion) and dronedarone (for prevention), are included, with specific contraindications for severe heart failure.
• Catheter ablation is suggested as a potential first-line treatment for selected patients with lone AF.

Conclusions:

• The updated Finnish guidelines provide a refined approach to atrial fibrillation management.
• Emphasis is placed on personalized risk assessment and the judicious use of new pharmacological and interventional therapies.
• These updates aim to improve patient outcomes by optimizing treatment strategies for AF.